Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis

The aims of this study were to assess the prevalence of, and risk factors for, Chlamydia trachomatis in attendees recruited prospectively from October 2018 to January 2019 at the only sexually transmitted infections clinic in Iceland (in Reykjavík), and to evaluate the cobas 4800 CT/NG Test and Apti...

Full description

Bibliographic Details
Main Authors: Ingibjorg Hilmarsdóttir, Eva Mjöll Arnardóttir, Elísabet Reykdal Jóhannesdóttir, Daniel Golparian, Magnus Unemo
Format: Article
Language:English
Published: Medical Journals Sweden 2021-02-01
Series:Acta Dermato-Venereologica
Subjects:
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3762
_version_ 1818300353303543808
author Ingibjorg Hilmarsdóttir
Eva Mjöll Arnardóttir
Elísabet Reykdal Jóhannesdóttir
Daniel Golparian
Magnus Unemo
author_facet Ingibjorg Hilmarsdóttir
Eva Mjöll Arnardóttir
Elísabet Reykdal Jóhannesdóttir
Daniel Golparian
Magnus Unemo
author_sort Ingibjorg Hilmarsdóttir
collection DOAJ
description The aims of this study were to assess the prevalence of, and risk factors for, Chlamydia trachomatis in attendees recruited prospectively from October 2018 to January 2019 at the only sexually transmitted infections clinic in Iceland (in Reykjavík), and to evaluate the cobas 4800 CT/NG Test and Aptima Combo 2 Assay for C. trachomatis detection in male urine and female vaginal swabs. Prevalence of C. trachomatis was 15.8% among 487 women and 13.6% among 491 men (no Neisseria gonorrhoeae positive patients were found). C. trachomatis detection was independently and positively associated with being tested for contact tracing, 18–24 years of age, and reporting ≥ 6 sexual partners within 12 months. Reporting sex with non-residents of Iceland was associated with a lower risk of C. trachomatis infection. Both assays had a high sensitivity in detection of C. trachomatis (Aptima Combo 2: 100%; cobas 4800 CT/NG: 95.1%) and high specificity (100% and 99.6%, respectively). The high local prevalence of C. trachomatis and increased acquisition risk following sex with residents are of public health concern.
first_indexed 2024-12-13T05:05:46Z
format Article
id doaj.art-15df8e1488994a6a8dc20f12ee30a1be
institution Directory Open Access Journal
issn 0001-5555
1651-2057
language English
last_indexed 2024-12-13T05:05:46Z
publishDate 2021-02-01
publisher Medical Journals Sweden
record_format Article
series Acta Dermato-Venereologica
spelling doaj.art-15df8e1488994a6a8dc20f12ee30a1be2022-12-21T23:58:40ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572021-02-011012adv0039310.2340/00015555-37626007Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for DiagnosisIngibjorg Hilmarsdóttir0Eva Mjöll ArnardóttirElísabet Reykdal JóhannesdóttirDaniel GolparianMagnus Unemo Department of Microbiology, Landspítali - The University Hospital of Iceland, 101 Reykjavik, Iceland. E-mail: ingibjh@landspitali.is. The aims of this study were to assess the prevalence of, and risk factors for, Chlamydia trachomatis in attendees recruited prospectively from October 2018 to January 2019 at the only sexually transmitted infections clinic in Iceland (in Reykjavík), and to evaluate the cobas 4800 CT/NG Test and Aptima Combo 2 Assay for C. trachomatis detection in male urine and female vaginal swabs. Prevalence of C. trachomatis was 15.8% among 487 women and 13.6% among 491 men (no Neisseria gonorrhoeae positive patients were found). C. trachomatis detection was independently and positively associated with being tested for contact tracing, 18–24 years of age, and reporting ≥ 6 sexual partners within 12 months. Reporting sex with non-residents of Iceland was associated with a lower risk of C. trachomatis infection. Both assays had a high sensitivity in detection of C. trachomatis (Aptima Combo 2: 100%; cobas 4800 CT/NG: 95.1%) and high specificity (100% and 99.6%, respectively). The high local prevalence of C. trachomatis and increased acquisition risk following sex with residents are of public health concern. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3762 chlamydia trachomatis neisseria gonorrhoeae prevalence risk factor nucleic acid amplification iceland sexually transmitted disease
spellingShingle Ingibjorg Hilmarsdóttir
Eva Mjöll Arnardóttir
Elísabet Reykdal Jóhannesdóttir
Daniel Golparian
Magnus Unemo
Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis
Acta Dermato-Venereologica
chlamydia trachomatis
neisseria gonorrhoeae
prevalence
risk factor
nucleic acid amplification
iceland
sexually transmitted disease
title Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis
title_full Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis
title_fullStr Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis
title_full_unstemmed Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis
title_short Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis
title_sort chlamydia trachomatis in iceland prevalence clinico epidemiological features and comparison of cobas 480 ct ng and aptima combo 2 ct ng for diagnosis
topic chlamydia trachomatis
neisseria gonorrhoeae
prevalence
risk factor
nucleic acid amplification
iceland
sexually transmitted disease
url https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3762
work_keys_str_mv AT ingibjorghilmarsdottir chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis
AT evamjollarnardottir chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis
AT elisabetreykdaljohannesdottir chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis
AT danielgolparian chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis
AT magnusunemo chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis